The invasion of bladder cancer into the sub-urothelial muscle and vasculature are key determinants leading to lethal metastatic progression. However, the molecular basis is poorly understood, partly because of the lack of uncomplicated and reliable models that recapitulate the biology of locally invasive disease. We developed a surgical grafting technique, characterized by a simple, rapid, reproducible and high-efficiency approach, to recapitulate the pathobiological events of human bladder cancer invasion in mice. This technique consists of a small laparotomy and direct implantation of human cancer cells into the bladder lumen. Unlike other protocols, it does not require debriding of the urothelial lining, injection into the bladder wall, specialized imaging equipment, bladder catheterization or costly surgical equipment. With minimal practice, the procedure can be executed in <10 min. Tumors develop with a high take rate, and most cell lines exhibit local invasion within 4 weeks of implantation.
Introduction
Invasive bladder cancer is deadly and is the sixth most common malignancy in the United States 1 and one of the most widespread carcinomas around the globe 2 . Patients with tumors exhibiting local muscle invasion (MI) and lymphovascular invasion (LVI) carry the worst prognosis for metastasis and death [3] [4] [5] [6] [7] . Advanced bladder cancer may initially respond to chemotherapy; however, remissions are not durable and cures are rare 3, 8 . Despite contemporary therapies, the median survival of 1 year for patients with metastatic bladder cancer following chemotherapy, has not been substantially improved for >3 decades. These facts illustrate the critical need to develop therapeutic strategies designed to inhibit bladder cancer in the early stages of invasion and prevent lethal metastasis. This requires biologically relevant, high-throughput models for preclinical evaluation of new therapies or approaches at various stages of tumor progression.
Although some very useful protocols exist for the establishment of orthotopic bladder cancer xenografts in mice 9, 10 , many of them suffer from obstacles that challenge their feasibility and reproducibility. First, they are time consuming, requiring specialized surgical equipment and a high level of technical skill. Researchers must be experienced with catheterization and ultrasound technology, and have a strong understanding of bladder anatomy to successfully execute the protocols. Second, most of the available protocols focus primarily on tumor growth and have not examined indepth pathobiological development of invasive human bladder cancer. To address these obstacles, our group developed a novel technique that exhibits local MI and LVI of human bladder cancer in the murine bladder. This protocol was recently used by Han et al. 11 to investigate the molecular mechanisms of muscle-invasive bladder cancer. This protocol is based on a simple and rapid implantation of bladder cancer cells through the bladder wall directly into the bladder lumen of mice ( Fig. 1) . We describe how to implement this model here.
Comparison with other mouse models of bladder cancer
Our orthotopic technique of direct bladder lumen injection is most similar to the intramural bladder wall xenograft protocol 12, 13 . Both techniques use laparotomies, expose the bladder and use needles to inject human bladder cancer cells. The most obvious difference is that the intramural technique requires precise placement of the cells in the bladder wall without puncturing the bladder mucosa. By contrast, our protocol first removes urine from the bladder to create consistent working conditions and to allow room for the cell suspension. This is followed by an injection through the bladder wall and mucosa directly into the luminal space of the mouse bladder. The luminal injection protocol is most useful when large numbers of mice are required and when a user wishes to look at tumor progression from the mucosal lining.
The presence of tumor cells within the bladder can be visualized on the day the tumor cells are implanted via fluorescence imaging, whereas the development of intra-bladder tumors can be followed in real time via bioluminescence in live animals over several weeks. Most of the human bladder cancer cell lines tested by our group developed invasive tumors in the bladder within 4 weeks while reproducing the key biological features of invasive human bladder cancer (Fig. 1) .
Even when exquisite alternative protocols for orthotopic xenotransplantation of bladder cancer cells exist, the technique described here offers several distinct advantages over existing comparable models (Table 1) . Our protocol is defined by a series of key features and steps that allow us to model the early invasive progression of human bladder cancer. Because this technique can be applied to both male and female adult mice and is not limited to female mice 9, 10, [13] [14] [15] [16] [17] , it better reflects disease that occurs in males and females. This contrasts with most previous models, which have reproduced tumor growth mostly in female mice, which is problematic because bladder cancer incidence is threefold higher in men than in women 1 . This protocol accurately reproduces the spontaneous invasive potential of individual cellular models. Sporadic spontaneous metastasis is also observed with this technique after 4 weeks of engraftment. Third, other models 9, 10, 12, 13, 18 have been validated using a few bladder cancer cell lines, with the KU-7 cells being the most commonly used, whereas we successfully reproduced our orthotopic xenotransplantation technique with 13 different bladder cancer cell lines. Unlike alternative protocols that depend on scarification of the luminal urothelium 9, 10, [14] [15] [16] [17] or injection into the bladder wall 10, 12, 13, [19] [20] [21] , our protocol recapitulates bladder cancer progression without chemical treatment of the luminal urothelium or major injury of the organ before implantation. Our method is also quicker to establish, as some alternative techniques require up to an hour for completion of surgery on one animal 9, 10, 12, 13 . Procedures based on catheterization and intravesical instillation also display high rates of procedure-related complications and animal mortality 9, 18 . By contrast, our model is rapid and easily mastered, making it amenable to larger high-throughput studies.
Potential applications of the protocol and future directions
The main purpose of this technique is to replicate the biology of human bladder cancer progression and the critical steps leading to local invasion into both the bladder musculature and the lymphovascular system. It can be used to examine general tumor progression, basic and translational tumor biology, and preclinical drug testing.
This technique is of special value to a broad array of scientists interested in tumor invasion and metastasis, or novel drug development, as well as those studying the molecular pathogenesis of bladder cancer. We and other molecular tumor biologists have utilized this model to interrogate the 11 . This technique has been successfully used by several laboratories at the University of Michigan. Currently, colleagues in medical oncology and pharmacology are using this model to evaluate drug formulation, delivery and efficacy. In addition, we are utilizing this protocol in collaboration with several biopharmaceutical companies interested in this technique for the evaluation of in vivo efficacy of experimental compounds and in the investigation of novel molecular targets. This protocol will be important in pharmaceutical research and academic research, as well as research in education and practical training in animal modeling.
The outlined technique is very versatile; beyond its applicability to human bladder cancer pathobiology studies, it can be adapted for the evaluation of drug efficacy or new bladder cancer therapies by direct instillation of drug into the bladder. For this purpose, survival experiments can also be designed using lower cell counts as inoculum and allowing the tumor to develop for extended periods of time. In addition, our research group is working on the optimization of a similar experimental design for the visualization and subsequent quantification of spontaneous metastasis. Early time points can also be used for the study of initial submucosal invasion within the mouse bladder visualized by standard immunohistochemical analysis or whole mounts.
Expertise needed to implement the protocol
Because of its simplicity, extensive technical ability and previous training are not necessary to execute this protocol. It is expected that any competent undergraduate student, graduate student, postdoc or technician could successfully follow the outlined protocol and rapidly become proficient.
Limitations
For the inoculation of human cancer cells into mice, immunocompromised mouse strains must be used to ensure that the tumor cells are not rejected by the recipient mouse. The relationship between cancer and the immune system has been very well documented 22, 23 . Thus, the requirement for immunocompromised mice, with attenuated immune components, remains a limitation for disease modeling and immunotherapy investigation in bladder cancer 24 . Another limitation is the engraftment of human cancer cells in a mouse host, which does not fully represent all aspects of human pathophysiology 24 . However, we have been able to recapitulate many of the invasive features of human bladder cancer progression using this xenograft technique. Therefore, by modeling critical features of human disease, our human-in-mouse model can efficiently be used for the pathobiological and preclinical evaluation of bladder cancer. In addition, post-surgical complications such as infection and tumor obstruction of the urethra or ureters can arise before the end point, requiring early sacrifice of the animal and loss of data; however this is rare.
Experimental design
Our orthotopic xenografting method is characterized by its simplicity, swiftness and ability to spontaneously reproduce the early events of human bladder cancer progression within the bladder microenvironment ( Fig. 1) , including local MI and LVI. Relying on a small laparotomy and direct inoculation of the cancer cells into the bladder lumen of mice (Fig. 2, Supplementary Video 1) , this process does not entail extensive damage to the urothelium or the bladder wall. In addition, the technique does not require special surgical or imaging equipment, special expertise, or critical anatomical knowledge.
Usually, the entire procedure, from anesthesia to the surgical end point, takes <10 min (Fig. 2 ). Although this protocol could be performed by one individual, we prefer a team of two to three, depending on available space and the number of animals included in the experiment. When we use a team, we distribute the work as follows. One person is responsible for the preparation of human cancer cells. While the cells are prepared, another person prepares the surgical space ( Supplementary  Fig. 1 ). When performing the surgeries, one person is responsible for monitoring the animals, recording important notes and preparing the syringes with cells, and the other individual(s) perform (s) the laparotomy and implantation. Distributing the tasks reduces the time required for the procedure, as well as the variability within the experiments and animal recovery.
During the procedure (Fig. 2, Supplementary Video 1) , the mouse is placed in dorsal recumbency. Then, a laparotomy with an incision size of 1 cm is performed to open the abdominal cavity to exteriorize the bladder. Minimizing the laparotomy incision size limits inflammation at the surgical site, and decreases the time needed to close the incision and the risk of infection. Once the bladder is located and exteriorized, the urine is aspirated from the apex with a syringe and the cellular suspension is injected into the empty lumen. These steps are the most critical and unique characteristics of our protocol, which does not require catheterization or assistance of special ultrasound equipment, . b, The surgical plane is cleared of hair with depilatory cream, and the skin is disinfected with iodine. c, A 1-cm incision is made through the skin and abdominopelvic wall, exposing the internal organs. d, The bladder is exteriorized. e, Urine is aspirated from the bladder, clearing the bladder lumen for inoculation. f, The diagram shows the needle placement during urine aspiration by piercing the dome of the bladder until the needle point is within the lumen. g, The base of the bladder is exposed by bringing the superior end of the bladder to the inferior end of the pelvic area. h, The needle is gently inserted into the bladder base until visualized in the vesical lumen. Then, the cancer cells are slowly injected. i, Needle placement during the intra-bladder implantation, by inserting the needle point into the region where the ureters drain into the organ. j, A cotton-tipped swab is used to absorb bodily fluids. k, The bladder is returned to the abdominopelvic cavity. The abdominal muscle and skin are sutured and closed. l, The skin is closed with surgical glue (as pictured) or wound clips. This procedure was approved by the Institutional Animal Care and Use Committee of the University of Michigan and followed the animal welfare recommendations of the National Institutes of Health.
denuding of the mucosa or extensive damage to the ventral bladder during implantation. Visualization of the injection process is also key to avoiding leakage and tumor seeding into the abdominopelvic cavity. After the cells are injected, the bladder is returned to the abdominal cavity and the laparotomy incision is closed using standard surgical methods. The mice are then allowed to wake from anesthesia, with the only restriction being that their water is withheld for 1 h, which reduces post-surgical urination, giving the cells time to adequately interact with the urothelium and seed into the bladder. Adaptations to the experimental design are required if different cellular models and murine strains are used. If a researcher is interested in using a cell line other than those mentioned here, we recommend running a pilot study. Although we discuss only the cell lines used by our group, we have successfully used many bladder cancer cell lines with this protocol. For a pilot study, the researcher must determine the optimal number of cells to inoculate and the time required for the tumors to develop. We recommend starting with a cell count of 1 × 10 6 cells per animal, with an experimental end point at 4 weeks. As the experiment nears completion, special attention should be given to the animal's overall health and behavior to ensure that the tumor is not causing the animal pain or distress. Once the experiment is completed and the histopathology has been analyzed, the optimal cell count and time of tumor development can be calculated. Besides broad utilization of non-obese diabetic/severe combined immunodeficient (NOD-SCID) mice, we have gained recent experience implementing this technique with NOD-SCID gamma (NSG) and nude mice, showing that these strains represent suitable alternative hosts. Therefore, this suggests that this model could be successfully adapted to other immunocompromised murine strains. If this protocol is standardized with a different strain, a pilot study should be performed first. This technique could also be adapted for utilization with humanized mice.
Controls
For this protocol, proper controls include age, gender and strain-matched mice to minimize biological variations. It is best to use mice from the same litter with the same date of birth whenever possible. Mice for our experiments generally ranged in age from 6 to 12 weeks old. Most commonly, bladder cancer develops in adults; thus, it is important to use mature adult mice for bladder cancer experiments. Although most of our work has been completed with NOD-SCID mice, alternative immunocompromised strains such as NSG and nude mice can be successfully used for this protocol. Finally, because bladder cancer affects men and women, sex as a biological variable should be addressed by using both male and female mice to have the best representation of patients. In addition, experimental controls must be included within the study. As this protocol is a surgical procedure, surgical controls, or sham mice, should be included in the experiment. The sham mice undergo the surgical procedure, but instead of injecting cells, saline or culture medium is injected into the bladder. These controls are especially important for comparing histological differences between mice with tumors and mice without tumors. When imaging the mice, it is important to include a negative control mouse with no bioluminescent or fluorescent signal. This will determine the background threshold. If this protocol is used for drug efficacy testing, a vehicle control group should also be included, as well as an untreated control group. The number of control animals should be kept to the lowest number necessary to achieve the experimental observations with the proper statistical power (P < 0.05).
Materials Biological materials
• Laboratory animals. We use NOD-SCID mice (NOD.CB17-Prkdc /SzJ) (Jackson Laboratory, cat. no. 005557) and nude mice (Charles River, cat. no. 490). We purchased breeders from the originating laboratory, and breeding was carried out by the Unit for Laboratory Animal Medicine (ULAM) Breeding core facility at the University of Michigan ! CAUTION All animal experiments should be performed in accordance with federal and local guidelines and regulations. Our experiments performed with animals were approved by the Animal Welfare Committee of the University of Michigan. Animals were housed in the ULAM housing facility in Ann Arbor, Michigan.
c CRITICAL The animals in our experiments range in age from 6 to 12 weeks old, and both male and female adult mice are used. The presence of thymic lymphoma is commonly observed in the NOD-SCID strain, and it should be monitored in all adult mice.
• Human bladder cancer cells. We have established orthotopic bladder xenografts with 13 human bladder cancer cell lines. In this protocol, we describe results from using the human transitional cell carcinoma lines UM-UC-6 (refs. 25, 26 ), UM-UC-9 (ref. 26 ) and UM-UC-13 (ref. 27 ), which were generously obtained from the originators (H.B. Grossman, University of Texas MD Anderson Cancer Center; and M. Liebert, University of Michigan) and banked in our laboratory. Human transitional cell carcinoma lines SW 780 (cat. no. CRL-2169) and T24 (cat. no. HTB-4) can be used and purchased from the American Type Culture Collection (ATCC). All cells should be grown in DMEM with high glucose, enriched with 10% (vol/vol) FBS, in a humidified incubator with an atmosphere of 5% CO 2 at 37°C c CRITICAL The identity of the cell lines should be genetically verified by restriction fragment length polymorphism. We tested the identity of our cells through the Research Animal Diagnostic Laboratory, Columbia, MO.
c CRITICAL All cells should be maintained for a limited number of passages and evaluated for Mycoplasma sp. contamination. We regularly test the cell lines using PlasmoTest (InvivoGen, cat. no. rep-pt1) before commencing with experiments. In addition, all cell lines were shown to be free of infectious agents by Charles River Research Animal Diagnostic Services.
Reagents
Cell culture • DMEM with L-glutamine (4 mM), sodium pyruvate (1 mM), phenol red and glucose (25 mM 
Reagent setup
Complete DMEM Mix 500 mL of DMEM with 50 mL of FBS in sterile flow hood. Store at 4°C for up to 1 year.
(Optional) Luciferase labeling Amplify the pLentipuro3/TO/V5-GW/EGFP-firefly luciferase plasmid and package into lentivirus. Transduce the lentivirus into bladder cancer cells as we previously described 28, 29 . The pLentipuro3/ TO/V5-GW/EGFP-firefly luciferase lentivirus plasmid is generated as follows: EGFP (from pEGFP-C1) and firefly luciferase (from pGL3-Basic) are amplified with Phusion High-Fidelity DNA polymerase and cloned into pENTR/D-TOPO using the Gibson Assembly Kit. The EGFP-luciferase coding region is recombined into pLentipuro3/TO/V5-DEST using LR Clonase II enzyme mix. The resultant pLentipuro3/TO/V5-GW/EGFP-firefly luciferase lentivirus plasmid is packaged (in our case, by the University of Michigan Vector Core) and transduced into bladder cancer cells as reported 28, 29 .
(Optional) Quantum dot labeling Fluorescently label bladder cancer cells using red or green quantum dots and following the Qtracker Cell Labeling Kit manufacturer's recommendations.
Animal welfare
Carprofen (Rimadyl; 5 mg/kg) can be stored under refrigeration (2-8°C for up to 6 months). Carprofen should be diluted to 0.05% (wt/vol) with saline solution (0.9% (wt/vol) NaCl) before use. c CRITICAL Always prepare working solutions fresh before each procedure.
Equipment setup

Surgical room
The Guide for the Care and Use of Laboratory Animals sets forth that any survival surgery performed on rodents or other small species should be executed in a space dedicated to only surgery or related activities. The area must be easily sanitized and not used for any other purpose than surgery for the full duration of the procedure. The surgery must be performed in an aseptic environment, with access to an isoflurane anesthesia machine and ventilator ( Supplementary Fig. 1 ). Ensure that enough isoflurane and medical oxygen are present to complete all surgeries.
Surgical preparation
Before initiating surgery, the following tools must be sterilized using a sterilization cassette (Supplementary Fig. 1 Place a warming pad at the nose cone, and place a sterile towel drape over the warming pad. Be sure that there is a sharps container and a container for garbage nearby for waste. Turn on the hot-bead sterilizer to sterilize tools between animals so that it reaches proper temperature for sterilization. Tools must be sterilized between animals of the same cage.
Animal preparation
Before initiation of the experiment, the lowest number of mice necessary for statistical power should be calculated. Only healthy mice that have been fully evaluated before surgery should be used. The day before the surgeries are to occur, the animals must be weighed, and they must receive an identifier (tattoo, ear tag and tail mark) that will remain for the duration of the experiment. The hair of NOD-SCID mice, and other furry strains such as NSG, must be removed at the incision site. We prefer to use depilatory lotion because it can fully remove the coat of animal fur ( Supplementary Fig. 2 ). Using a dime size (18 mm) amount of lotion, remove the hair by working into the fur, using a quick but gentle, circular motion. Rinse and remove any excess lotion left on the animal, as prolonged contact can irritate the animal's skin. ! CAUTION The protocol must be approved by the institute's Animal Care and Use Committee. All animals must receive humane care according to the criteria outlined in the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals. c CRITICAL Do not remove fur on the day of surgery, as wet fur can lead to hypothermia while the animals are under anesthesia. Clipping is the only acceptable alternative to a depilatory lotion for removal of the mouse hair. Do not shave the animals; small lacerations can lead to infections at the incision site.
Animal housing
House animals under standard housing conditions in ventilated cages. Immediately following surgery, place mice in a cage on a warming pad to assist in recovery and withhold water for 1 h. Following surgery and successful recovery from anesthesia, mice that were previously housed together can remain together. Do not place mice that have incisions in the same cage as mice that did not undergo surgery, as this could lead to fighting and the recovering animals within the cage could be harmed.
Procedure Preparation of human bladder cancer cells • Timing~15 min
1 Before commencing work with cells, pre-warm PBS, supplemented culture medium and TrypLE to room temperature (23°C). Prepare a bucket of ice. 2 Aspirate culture medium from plates of healthy cells at 60-80% confluence.
! CAUTION Cancer cells are a biohazard and must be handled with care. Wear gloves, lab coat and eye protection when handling. This procedure must be performed only under a laminar flow hood. c CRITICAL To maintain sterility, all cell work must be performed under a laminar flow hood. 3 Detach cells from the plate with nonenzymatic cell dissociation solution, TrypLE. Ensure that the TrypLE solution covers the full area of the dish. Place the dish in a 37°C incubator. c CRITICAL STEP Our lab has worked with trypsin and TrypLE when preparing cells for animal inoculation and have repeatedly found a better tumor take when TrypLE is used as the dissociation reagent. It is gentler on cells and does not denude the surface proteins critical for adhesion to the bladder mucosa. After 3-5 min of incubation, monitor cell dissociation with an inverted bright-field microscope. c CRITICAL STEP Incubating the cells for too long could lead to decreased viability and, unsuccessful or reduced xenograft development. Incubation time with TrypLE will vary among cell lines, and close monitoring under a microscope should be performed to determine the optimal time for each line. ? TROUBLESHOOTING 4 Once cells have detached, add culture medium to the dish to neutralize the TrypLE. Be sure to thoroughly mix the suspension. Pipette the cell suspension up and down rapidly to break up clumps, and wash the dish sides to remove any remaining cells. 5 Pipette the cell suspension into a 15-or 50-mL sterile centrifuge tube and mix well until a uniform suspension is achieved. c CRITICAL STEP Great care must be taken to accurately determine the cell count and maintain uniformity between intra-bladder injections. ? TROUBLESHOOTING j PAUSE POINT Cells can be kept on ice for up to 3 h.
Preparation for surgery • Timing~3 min per mouse
! CAUTION All animal experiments must conform to relevant local and national guidelines and regulations. All surgical procedures should be performed in a designated surgical space. There should be one autoclaved tool pack per cage of mice. 13 Record mouse weights and provide pre-emptive analgesic carprofen (5 mg/kg) 1 h before administration of anesthesia. 14 Place the mouse in the induction chamber with~5.0% (vol/vol) isoflurane until fully anesthetized.
! CAUTION Isoflurane can be hazardous if overexposure occurs. Ensure that charcoal filters are in place to collect waste gas fumes. 15 Reduce isoflurane flow to~2.0% (vol/vol) for maintenance, apply ophthalmic ointment and transfer the mouse to a nose cone on a surgical plane. c CRITICAL STEP Adjust the isoflurane concentration to between 1.5 and 2.5% (vol/vol) according to the size of the mouse. Larger males will generally require a higher concentration of isoflurane than smaller female mice. Ensure that the mouse is fully asleep by testing that reflexes are lost via toe-pinch reflex. 16 Clean and disinfect the surgical site on the animal with povidone-iodine solution. Allow the solution to sit on the skin for 5-10 s and then wipe away with alcohol wipes. Repeat this step three times.
? TROUBLESHOOTING
Surgical orthotopic implantation • Timing~4 min per mouse
! CAUTION Tools should be sterilized with a Germinator between animals from the same cage.
c CRITICAL A full description of the surgical technique described in this section is provided in Supplementary Video 1. 17 Make a 1-cm midline incision through the skin of the abdominopelvic region (Fig. 2a,b) by grasping only the skin layer with the Adson forceps and cutting with the iris scissors. Separate the skin and muscle layers surrounding the incision with the Adson forceps and the pointed forceps. 18 Section the exposed abdominal wall by making a 1-cm incision with the iris scissors and following the white midline known as linea alba (Fig. 2c) . Use the Adson forceps to hold the tissue while cutting. This will generate a small opening of the abdominopelvic cavity. Place sterile gauze around the incision to maintain the sterility of the mouse's surgical plane. c CRITICAL STEP When entering the abdominopelvic cavity to approach the urinary bladder, minimize blood loss and nerve damage by making a midline incision through the linea alba. This is a fibrous structure with poor vascularization. 19 Locate the urinary bladder. It is found near the distal end of the incision (or hypogastric region), behind fatty tissue and the large intestine. Gentle pressure lateral to the incision may cause it to rise up through incision. Fully distended bladders will be easier to locate (Fig. 2d) . However, if the animal has recently urinated, locating the bladder can be difficult for inexpert personnel because of its small size. Once located, use pointed forceps to gently grasp and exteriorize the bladder. Typically, pointed forceps can grasp the serosal peritoneum of the bladder, although ceramic-coated cupped forceps can also be used to grasp the body of the bladder. c CRITICAL STEP Be extremely gentle with internal organs and tissues. Excessive or aggressive handling can increase inflammation and pain at the surgical site. 20 Keep hold of the bladder with either the pointed or ceramic-coated cupped forceps. Insert a 30 1/2-gauge needle with a syringe attached into the dome of the bladder to aspirate the urine (Fig. 2e,f) . ? TROUBLESHOOTING 21 While still keeping hold of the bladder with the pointed or ceramic-coated cupped forceps, expose the inoculation site by bringing the superior end of the bladder to the inferior end of the abdominal cavity (Fig. 2g) . Using a 30 1/2-gauge needle attached to a 1-mL syringe filled with the cellular suspension, pierce the base of the bladder (Fig. 2h) . c CRITICAL STEP To prevent lesions, pierce the bladder in a different area from that used for urine removal (Step 21) and avoid ureters. We have tried diverse areas of inoculation within the bladder body and have observed equal results. We prefer to pierce the bladder base, where the muscle wall is thicker, to help retain the injected cellular suspension and avoid bladder leakage. ? TROUBLESHOOTING 22 Before pressing the plunger of the syringe, be sure to visualize the needle point within the distal lumen of the bladder. Once visualized, inject 50 μL of cellular suspension into bladder lumen (Fig. 2h,i) and use a sterile cotton swab to absorb any fluid at the injection site. c CRITICAL STEP When preparing syringes with cellular suspension, mix the suspension well to ensure that the same number of cells are injected into each animal. Ensure that little to no dead space remains in the syringe and needles with cells. ? TROUBLESHOOTING 23 Place the bladder back inside the body cavity and make sure that all other organs are in their proper places. Again, use a sterile cotton-tipped swab to absorb excess fluid and blood in the abdominopelvic cavity (Fig. 2j) . Pull up the abdominal tissue layers on each side (including the abdominal muscle, connective tissue and peritoneum; this is observed as a thick muscular layer by the surgeon). 24 Close the abdominopelvic cavity by suturing the muscle and associated layers. Our lab utilizes a continuous, absorbable suture to close the abdominal wall (Fig. 2k, Supplementary Fig. 3 ). ? TROUBLESHOOTING 25 Close the skin layer using surgical adhesive or autoclips and ensure that the incision is fully sealed (Fig. 2l) . ? TROUBLESHOOTING 26 Remove the animal from the isoflurane nose cone, return the animal to its cage with a warming pad underneath and allow the animal to recover.
Post-surgical recovery and follow-up • Timing~10 min for recovery from anesthesia and 10 min following the surgical procedure ! CAUTION Surgical records monitoring animal recovery should be filled out according to national and institutional regulations. 27 Monitor the animals as they wake up from anesthesia, but do not allow them to have water. c CRITICAL STEP Ensure that all animals are awake in each cage before ending the post-surgical monitoring period. Mice will attack cage mates that are unconscious for too long. ? TROUBLESHOOTING 28 1 h following surgery, check on the mice again and return water to the cage containing mice. c CRITICAL STEP Limiting the post-surgical water intake to a minimum is critical to prevent urination of the recently injected cancer cells and allow maximum interaction with the bladder mucosa while promoting the recovery of the mice. However, if the water consumption is restricted for longer periods of time, it could severely affect the animals during post-surgical recovery, causing dehydration and shock. 29 Monitor wound healing ( Supplementary Fig. 4 ) and recovery.
Troubleshooting
Troubleshooting advice can be found in Table 2 and Supplementary Fig. 5 . Mice urinate cell suspension, not allowing the cells enough time to seed Insufficient aspiration of urine before inoculation Excess air in the syringe during inoculation Injection of a cellular suspension volume that is too large for the bladder to hold Animals had access to water following surgery Aspirate all urine from the bladder, so the only fluid present is cell suspension Ensure that no air bubbles are present in the syringe. Air could fill the bladder with empty space, increasing the animal's urge to urinate Withhold fluids for 1 h post inoculation Limit the injection volume to 50 µL 21 and 22 Tumor growth observed outside of the bladder ( Supplementary  Fig. 5b ) Cellular suspension does not reach the bladder during inoculation Cellular suspension leaks from the bladder, which was accidentally perforated during surgery Use a cotton swab at the base of the bladder to absorb any excess fluid spilled out during inoculation Handle the bladder with extreme caution. Use fine-tipped forceps to grasp a small piece of connective tissue when manipulating the bladder. During aspiration and injection, maintain visualization of the needle point to avoid perforating the bladder wall 24 and 25 Improper wound healing ( Supplementary Fig. 5a ) This could be due to poor wound closure. Our protocol involves running a continuous suture through the abdominal muscle layer and then applying surgical tissue glue to close the skin layer Use of too much glue can irritate the animals, causing them to pick at the incision. Never reapply glue. If the incision opens following surgery and there is no sign of infection or irritation of the skin, it is best to leave the incision to heal. See Supplementary Fig. 5a Timing Steps 1-12, preparation of human bladder cancer cells:~15 min Steps 13-16, preparation for surgery:~3 min per mouse Steps 17-26, surgical orthotopic implantation:~4 min per mouse Steps 27-29, post-surgical recovery and follow-up:~10 min for recovery from anesthesia and 10 min following the surgical procedure
Anticipated results
Post-surgical monitoring of mice is critical for overall experimental success. Our institute requires daily monitoring of mice for 10 d following the surgical procedure. We recommend continuing this monitoring schedule for the duration of the experiment to ensure the health and recovery of the animals. Check the surgical incision daily to ensure that it is healing and there are no signs of infection ( Supplementary Fig. 4 ). Weigh the animals at least weekly and note fluctuations in the animal's weight. If significant discomfort or weight loss is observed, the animals should be allowed supportive care, such as fluid administration and/or diet gel. The development of the tumor in the bladder must also be monitored. The monitoring schedule can be weekly at first; however, as the experiment progresses, we recommend monitoring the tumor development daily. To monitor the tumor's growth in the animal, perform gentle palpations of the bladder by pressing down on the abdominopelvic cavity.~1 week following implantation, the bladder tumor should be palpable. In addition, while palpating the bladder, ensure that the animal is able to urinate by gently pressing on the bladder and observing the release of urine. If the animal is not able to urinate or significant hematuria is observed, euthanize the animal. The evolving needs of the experiment will dictate whether to perform bioluminescence or fluorescence in vivo imaging to check the success of the inoculation and follow the development of the intra-bladder tumors (Fig. 3a,b) . We utilized the IVIS Spectrum Optical Imaging System for all in vivo imaging because this system has the capability to capture both bioluminescent and fluorescent signals. In general, we recommend using cells labeled with quantum dots for experiments requiring early time points (<1 week) and cells tagged with luciferase for experiments requiring longer time points (>1 week). However, we have seen a fluorescent quantum dot signal as early as the day of inoculation and a bioluminescent signal <1 week following inoculation.
The number of inoculated cells must be determined on the basis of the aggressiveness and in vivo proliferation of each cell line. We suggest starting with 0.5-1 × 10 6 cells and increasing the number if the tumors do not develop after 4 weeks. When inoculating 0.5-5 × 10 6 cells per mouse, we have found that extending the experiments longer than 4 weeks often leads to mice with obstruction of the urinary bladder due to aggressive tumor development. The most important symptoms of an obstructed bladder in the mouse include distended abdomen, inability to urinate or the ability to urinate only small drops, and hematuria. Other associated signs, such as shakiness, lethargy and low body temperature, and pale eyes, ears and gums may also be present. In such cases, the mice should be euthanized immediately.
After 4 weeks of tumor development in vivo, the mice should be euthanized according to guidelines, and tissues of interest should be collected at necropsy. Ex vivo bioluminescence or fluorescence imaging can be performed, as well as photography of excised bladders with a dissection microscope for gross examination of the specimen (Fig. 3) . Bladders should be fixed in formalin and paraffin-embedded until ready for immunohistochemical and histopathological analysis (Fig. 3c) .
Following the technique described in this protocol, human bladder cancer cell lines develop locally invasive intra-bladder tumors 4 weeks after transplantation. The establishment of orthotopic bladder cancer xenografts is summarized in Table 3 . We followed the presence of bladder tumors before the experimental end point using different methods. UM-UC-9 xenografts were detected by bioluminescence (Fig. 3a) and, UM-UC-6 and SW 780 xenografts were detected by bioluminescence or quantum dot fluorescence (Fig. 3b) . We also corroborated the incidence of intravesical tumors by ex vivo imaging and histological assessment (Fig. 3c) . Overall, the xenografts modeled with the orthotopic surgical technique yielded high implantation rates. We successfully established SW 780, UM-UC-6 and UM-UC-9 tumors in 100% of the NOD-SCID mice after intravesical injection of 1 million cells (Table 3) . Interestingly, in preliminary pilot studies, we observed a reduction in the incidence of UM-UC-9 tumors according to the number of cells injected. Among these mice, the grafting success rate was 61-93% when 0.2-0.6 million cells per mouse were inoculated (Table 3) . Additional pilot studies with NSG and nude mice were also performed. A total of 11 NSG mice and five nude mice were inoculated intravesically with 1 million UM-UC-9 cells (Supplementary Fig. 6 , Table 3 ). Despite these strains not yet being established models, we have successfully grafted tumors in 100% of the mice, thus indicating that NSG and nude strains have solid potential to serve as alternative modeling hosts.
At the histological level, the xenografted cell lines showed an aggressive growth pattern characterized by solitary intra-bladder tumors invading the bladder submucosa and exhibiting local muscle and LVI. These key microscopic characteristics are represented in Fig. 4 . Of particular interest, the microscopic examination of UM-UC-9, UM-UC-6 and SW 780 tumors displayed a deep extent of invasion into the bladder wall (Fig. 5a ). Cytokeratin 8 (CK8) tumor cells invaded beyond the lamina propria with clear infiltrates into the muscular layer. These observations represent muscleinvasive T2, and occasionally T3, staged tumors. In all, the tumors exhibited marked cellular atypia with evident architectural irregularities, high mitotic activity and pleomorphism. The pathological sections also showed frequent tumor emboli within the lymphovascular spaces when MI was present (Fig. 5b) . These distinctive histological features of the implanted tumors resemble the key pathobiological characteristics of human tumors, including MI and LVI (Fig. 5c) . Typical results from our previously established UM-UC-3 and T24 models 11 are shown in Supplementary Fig. 7 ; these cell lines show less aggressive traits. The extent of MI should be assessed by recording the maximum anatomic depth of tumor invasion in a manner analogous to staging of human bladder cancers: (i) invasion of the inner half of the muscularis propria; (ii) invasion of the outer half of the muscularis propria; (iii) microscopic invasion of the perivesicular adipose tissue and (iv) gross invasion of the perivesicular adipose tissue. The extent of LVI should be assessed by counting the total number of hCK8 + tumor emboli in mCD31 and mLYVE1 + lymphovascular spaces in five representative sections of tumor.
Although not the focus of this protocol, other sporadic observations have been made using this technique, such as noninvasive intraepithelial lesions of the bladder ( Supplementary Fig. 8a,b) and spontaneous metastasis when allowing tumor development through the 4th week (Supplementary Fig. 8c ). Most frequently, we have observed distant metastasis in the liver and lungs.
In all, our orthotopic bladder cancer xenografts in mice allow us to model the early key features of spontaneous human bladder cancer invasion. We have shown that human bladder cancer cells are able to seed in their natural bladder niche without further requirements and spontaneously recapitulate MI and LVI, which are well-known histological features of aggressive human disease. Thus, this reproducible and simple technique efficiently models human bladder cancer invasion and represents a valuable tool for dissecting the cellular and molecular mechanisms that regulate the invasive progression of human bladder cancer. 
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